Market Overview

UPDATE: JP Morgan Downgrades Life Technologies to Neutral Pending Visibility on Emerging and Applied Markets

Related LIFE
aTyr Pharma Initiates Phase 1b/2 Clinical Trial for Patients with Limb Girdle Muscular Dystrophy 2B
aTyr Pharma Announces Change in Leadership

JP Morgan lowered its rating on Life Technologies (NASDAQ: LIFE) from Overweight to Neutral and reduced its price target from $52, to $46.

JP Morgan commented, "Since the merger of ABI and IVGN, we have seen a series of missteps from LIFE, as the company has failed to adequately compete against ILMN in sequencing, or move nimbly enough into applied markets and away from the challenged research end market. With management expecting both a benefit from the roll-off of FX hedges, and ramp in growth in 2H12, aided by Ion Proton, we believe it is prudent to move to the sidelines, as we continue to see academic research budgets in the U.S. and Europe as being under pressure. We look to consider becoming more constructive pending improved visibility on the sequencing franchise, as well as a comprehensive strategy to increase margins and exposure to emerging and applied markets."

Life Technologies closed at $41.26 on Tuesday.

Latest Ratings for LIFE

Jun 2015JP MorganInitiates Coverage onOverweight
Aug 2013BairdDowngradesOutperformNeutral
May 2013Credit AgricoleDowngradesOutperformUnderperform

View More Analyst Ratings for LIFE
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Downgrades Price Target Pre-Market Outlook Analyst Ratings


Related Articles (LIFE)

View Comments and Join the Discussion!

Get Benzinga's Newsletters